id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-1284-0003,FDA,FDA-2024-E-1284,Letter from U.S. Patent and Trademark Office to Fish & Richardson P.C.,Other,Letter(s),2024-04-10T04:00:00Z,2024,4,2024-04-10T04:00:00Z,,2024-04-10T16:04:51Z,,0,0,09000064864c046d
FDA-2024-E-1284-0001,FDA,FDA-2024-E-1284,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:54:53Z,,0,0,090000648647d892
FDA-2024-E-1284-0002,FDA,FDA-2024-E-1284,"Patent Term Extension Application for ADZYNMA Patent No 7,517,522",Other,Application,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:55:23Z,,0,0,090000648647d8e9